Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing the consent form
- People who have been diagnosed with a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that cannot be removed by surgery and/or has spread to other parts of the body
- People whose lung cancer has a specific genetic change (mutation) in a gene called HER2 that is known to drive cancer growth
- People who have a general health/activity level rated as 0, 1, or 2 on a standard medical scale (meaning able to carry out some or all daily activities) (confirm with trial site)
- People who are receiving, or have very recently started (within the last 2 months), a treatment called T-DXd, based on their doctor's decision
Who may not be able to join:
- People who have previously been treated with certain HER2-targeted therapies, including specific medicines that block HER2 signals (called tyrosine kinase inhibitors targeting HER2 mutations — though a broader class called pan-HER TKIs may be acceptable), or antibody-drug treatments (ADCs) that carry a particular type of chemotherapy agent (confirm with trial site)
- People who have spinal cord compression, or brain/nervous system cancer spread that is untreated and causing symptoms, or that requires steroid or anti-seizure medicines to manage symptoms
- People who have serious or poorly controlled overall health conditions, such as uncontrolled high blood pressure or active uncontrolled bleeding problems
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Project Manager, Daiichi Sankyo Co., Ltd.
Phone: 908-992-6400
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival (PFS) by Investigator Assessment in Real-world Setting (rwPFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.